| Recruiting | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Adenocarcinoma, Carcinoma, Pancreatic Ductal | Phase 2 | 2026-01-27 |
| Recruiting | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies Neoplasms | Phase 1 / Phase 2 | 2026-01-16 |
| Completed | Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Sub Healthy | Phase 1 | 2025-09-11 |
| Recruiting | Evaluation of Miricorilant on Liver Fat in Patients With MASLD Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 1 | 2025-08-22 |
| Recruiting | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms | Phase 2 | 2025-04-11 |
| Completed | Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM) Resistant Hypertension, Hypercortisolism | — | 2025-03-28 |
| Completed | Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant Hepatic Impairment | Phase 1 | 2024-10-08 |
| Completed | Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants Healthy Adults | Phase 1 | 2024-05-31 |
| Active Not Recruiting | A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfun Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | 2023-10-25 |
| Completed | Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korl Hypercortisolism, Diabetes Mellitus, Type 2 | Phase 4 | 2023-03-31 |
| Completed | Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH) | Phase 1 | 2023-01-24 |
| Recruiting | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis | Phase 2 | 2022-11-15 |
| Active Not Recruiting | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms | Phase 3 | 2022-06-29 |
| Completed | Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate Cushing Syndrome, Neoplasms | Phase 1 | 2022-05-25 |
| Completed | A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients Wit Nonalcoholic Steatohepatitis (NASH) | — | 2022-03-04 |
| Completed | Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant Non-alcoholic Steatohepatitis (NASH) | Phase 1 | 2022-03-03 |
| Completed | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalc Nonalcoholic Steatohepatitis (NASH) | Phase 1 | 2021-11-23 |
| Completed | Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Part Healthy | Phase 1 | 2021-08-18 |
| Completed | Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants Healthy | Phase 1 | 2021-08-03 |
| Completed | Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants Healthy Adults | Phase 1 | 2021-07-13 |
| Completed | T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers Healthy | Phase 1 | 2021-01-22 |
| Terminated | Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nona Nonalcoholic Steatohepatitis (NASH) | Phase 2 | 2020-11-04 |
| Completed | Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants Healthy | Phase 1 | 2020-10-23 |
| Completed | Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produ Adrenocortical Carcinoma | Phase 1 | 2020-09-30 |
| Completed | A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects Healthy | Phase 1 | 2020-09-19 |
| Completed | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Sch Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | 2020-09-09 |
| Completed | A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas Hypercortisolism | Phase 3 | 2020-07-27 |
| Terminated | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenoca Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | 2020-06-30 |
| Completed | Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants Healthy | Phase 1 | 2020-04-27 |
| Completed | Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants Healthy Adults | Phase 1 | 2020-01-27 |
| Completed | A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant Hepatic Impairment | Phase 1 | 2020-01-06 |
| Completed | A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | 2019-12-04 |
| Completed | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovaria Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma | Phase 2 | 2019-04-05 |
| Completed | The Effect of CORT118335 on Olanzapine-Induced Weight Gain Antipsychotic-induced Weight Gain | Phase 1 | 2019-04-01 |
| Completed | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Cushing Syndrome | Phase 3 | 2018-11-15 |
| Completed | Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants Healthy | Phase 1 | 2018-09-13 |
| Completed | Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants Healthy | Phase 1 | 2018-08-06 |
| Completed | A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants Healthy | Phase 1 | 2018-05-24 |
| Active Not Recruiting | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Cushing Syndrome | Phase 2 | 2018-05-07 |
| Completed | Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metaboli Healthy | Phase 1 | 2018-04-10 |
| Completed | Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochro Healthy | Phase 1 | 2018-03-06 |
| Completed | Relacorilant Food Effect Study in Healthy Subjects Healthy, Food-drug Interaction | Phase 1 | 2018-01-16 |
| Completed | Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC Metastatic Castration-Resistant Prostate Cancer | Phase 1 / Phase 2 | 2017-12-15 |
| Completed | CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Healthy | Phase 1 | 2017-09-21 |
| Terminated | Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome Hypercortisolism, Cushing Syndrome | — | 2017-09-18 |
| Completed | First-in-human Study in Healthy Subjects Healthy | Phase 1 | 2017-09-15 |
| Completed | Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone a Healthy | Phase 1 | 2017-08-16 |
| Completed | Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor Drug Interaction Potentiation, Healthy | Phase 1 | 2017-08-09 |
| Completed | A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects Healthy | Phase 1 | 2017-05-18 |
| Completed | Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery Cushing's Syndrome | — | 2016-11-01 |
| Completed | A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body Healthy | Phase 1 | 2016-08-01 |
| Completed | Study to Evaluate CORT125134 in Participants With Cushing's Syndrome Cushing's Syndrome | Phase 2 | 2016-06-01 |
| Completed | Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumo Solid Tumors | Phase 1 / Phase 2 | 2016-05-23 |
| Completed | A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects Healthy | Phase 1 | 2016-04-07 |
| Completed | Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome Cushing's Syndrome | — | 2015-10-01 |
| Completed | CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Healthy | Phase 1 | 2014-09-01 |
| Completed | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid T Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma | Phase 1 | 2014-01-01 |
| Withdrawn | Mifepristone in Children With Refractory Cushing's Disease Cushing's Disease | Phase 3 | 2013-08-01 |
| Completed | Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syn Cushing's Disease, Cushing's Syndrome | Phase 3 | 2010-11-01 |
| Completed | An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Cushing's Syndrome | Phase 3 | 2009-07-01 |
| Terminated | A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercorti Cushing's Syndrome | — | 2009-02-01 |
| Completed | A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers Healthy | Phase 1 | 2008-11-01 |
| Completed | A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volu Healthy Subjects | Phase 1 | 2008-09-01 |
| Terminated | A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis | Phase 3 | 2008-03-01 |
| Completed | A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Cushing's Syndrome | Phase 3 | 2007-12-01 |
| Completed | A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gai Weight-Gain Prevention | Phase 2 | 2007-03-01 |
| Completed | An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression Major Depressive Disorder, Psychotic Disorders | Phase 3 | 2005-08-01 |
| Completed | An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depr Major Depressive Disorder | Phase 3 | 2005-05-01 |
| Completed | A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression Depressive Disorder, Major | Phase 3 | 2005-05-01 |
| Completed | A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depre Major Depressive Disorder, Psychotic Disorders | Phase 3 | 2004-09-01 |
| Completed | A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression Major Depressive Disorder, Psychotic Disorders | Phase 3 | 2004-09-01 |
| Terminated | Mifepristone as Adjunctive Therapy in Alzheimer's Disease Alzheimer's Disease | Phase 2 | 2003-04-01 |